Astellas Pharma (OTCMKTS:ALPMY) Announces Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) released its quarterly earnings data on Tuesday. The company reported $0.30 earnings per share (EPS) for the quarter, Zacks reports. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.40%.

Astellas Pharma Stock Up 1.6 %

ALPMY stock opened at $9.30 on Thursday. Astellas Pharma has a 12 month low of $9.05 and a 12 month high of $13.14. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.10 and a quick ratio of 0.86. The company has a market cap of $16.83 billion, a price-to-earnings ratio of 44.29 and a beta of 0.34. The company has a fifty day moving average price of $9.84 and a 200 day moving average price of $10.96.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.